Document is current

Any future updates will be listed below

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced or recurrent endometrial cancer in Japan

Crossref DOI link: https://doi.org/10.1007/s10147-024-02679-w

Published Online: 2024-12-28

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark